Intravascular inhibition of factor VIIa and the analogue NN1731 by antithrombin

British Journal of Haematology

Volumn 152, Issue 1, 2011, Pages 99-107

  Petersen, Lars C ^a   Karpf, Ditte M ^a   Agersø, Henrik ^a   Hermit, Mette B ^a   Pelzer, Hermann ^a   Persson, Egon ^a   Nichols, Timothy C ^b   Ezban, Mirella ^a  

^a NOVO NORDISK A S   (Denmark)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antithrombin; Factor VIIa

Indexed keywords

HEPARIN; NN 1731; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; WESTERN BLOTTING;

ANIMALS; ANTITHROMBIN PROTEINS; BLOOD COAGULATION; BLOOD COAGULATION FACTOR INHIBITORS; COAGULANTS; DISEASE MODELS, ANIMAL; DOGS; FACTOR VII; FACTOR VIIA; HALF-LIFE; HEMOPHILIA A; MALE; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY;

EID: 78650020680     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08432.x     Document Type: Article

References (27)

1. Allen, G.A., Persson, E., Campbell, R.A., Ezban, M., Hedner, U. & Wolberg, A.S. (2007) A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 683-689.
2. Berntorp, E. (2009) Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia: The Official Journal of the World Federation of Hemophilia, 15, 3-10.
3. Brinkhous, K.M., Hedner, U., Garris, J.B., Diness, V. & Read, M.S. (1989) Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. Proceedings of the National Academy of Sciences of the United States of America, 86, 1382-1386.
4. Erhardtsen, E. (2000) Pharmacokinetics of recombinant activated factor VII (rFVIIa). Seminars in Thrombosis and Hemostasis, 26, 385-391.
5. Hamamoto, T. & Kisiel, W. (1998) The effect of cell surface glycosaminoglycans (GAGs) on the inactivation of factor VIIa tissue factor activity by antithrombin III. International Journal of Hematology, 68, 67-78.
6. Hayashi, T., Tanaka, I., Shima, M., Yoshida, K., Fukuda, K., Sakurai, Y., Matsumoto, T., Giddings, J.C. & Yoshioka, A. (2004) Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Haemophilia: The Official Journal of the World Federation of Hemophilia, 10, 397-400.
7. Hedner, U. & Brun, N.C. (2007) Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent. Neuroradiology, 49, 789-793.
8. Holmberg, H.L., Lauritzen, B., Tranholm, M. & Ezban, M. (2009) Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice. Journal of Thrombosis and Haemostasis, 7, 1517-1522.
9. Johansen, P.B., Bjørn, S.E., Agersø, H., Thorup, I., Hermit, M.B., Sørensen, B.B., Stennicke, H.R., Ezban, M. & Tranholm, M. (2010) Prolonged effect of GlycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma. Thrombosis and Haemostasis, 104, 157-164.
10. Kondo, S. & Kisiel, W. (1987) Regulation of factor VIIa activity in plasma: evidence that antithrombin III is the sole plasma protease inhibitor of human factor VIIa. Thrombosis Research, 46, 325-335.
11. Lawson, J.H., Butenas, S., Ribarik, N. & Mann, K.G. (1993) Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. Journal of Biological Chemistry, 268, 767-770.
12. Lindley, C.M., Sawyer, W.T., Macik, B.G., Lusher, J., Harrison, J.F., Bairdcox, K., Birch, K., Glazer, S. & Roberts, H.R. (1994) Pharmacokinetics and pharmacodynamics of recombinant factor viia. Clinical Pharmacology and Therapeutics, 55, 638-648.
13. Mast, A.E., Enghild, J.J., Nagase, H., Suzuki, K., Pizzo, S.V. & Salvesen, G. (1991) Kinetics and physiologic relevance of the inactivation of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, and antithrombin III by matrix metalloproteinases-1 (tissue collagenase), -2 (72-kDa gelatinase/type IV collagenase), and -3 (stromelysin). Journal of Biological Chemistry, 266, 15810-15816.
14. Morrissey, J.H., Macik, B.G., Neuenschwander, P.F. & Comp, P.C. (1993) Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood, 81, 734-744.
15. Moss, J., Scharling, B., Ezban, M. & Sorensen, T.M. (2009) Evaluation of the safety and pharmacokinetics of a fast- acting recombinant FVIIa analogue, NN1731, in healthy male subjects. Journal of Thrombosis and Haemostasis, 7, 299-305.
16. Olson, S.T., Swanson, R., Raub-Segall, E., Bedsted, T., Sadri, M., Petitou, M., Hérault, J.P., Herbert, J.M. & Björk, I. (2004) Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin. Thrombosis and Haemostasis, 92, 929-939.
17. Persson, E., Kjalke, M. & Olsen, O.H. (2001) Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proceedings of the National Academy of Sciences of the United States of America, 98, 13583-13588.
18. Petersen, L.C., Elm, T., Ezban, M., Krogh, T.N., Karpf, D.M., Steinø, A., Olsen, E.H. & Sørensen, B.B. (2009) Plasma elimination kinetics for factor VII are independent of its activation to factor VIIa and complex formation with plasma inhibitors. Thrombosis and Haemostasis, 101, 818-826.
19. Sørensen, B. & Ingerslev, J. (2004) Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. Journal of Thrombosis and Haemostasis, 2, 102-110.
20. Sorensen, B.B., Persson, E., Freskgard, P.O., Kjalke, M., Ezban, M., Williams, T. & Rao, L.V.M. (1997) Incorporation of an active-site inhibitor in factor viia alters the affinity for tissue factor. Journal of Biological Chemistry, 272, 11863-11868.
21. Sørensen, B., Persson, E. & Ingerslev, J. (2007) Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. British Journal of Haematology, 137, 158-165.
22. Spiezia, L., Rossetto, V., Campello, E., Gavasso, S., Woodhams, B., Tormene, D. & Simioni, P. (2010) Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis. Thrombosis and Haemostasis, 103, 1188-1192.
23. Tarnow, I., Falk, T., Tidholm, A., Martinussen, T., Jensen, A.L., Olsen, L.H., Pedersen, H.D. & Kristensen, A.T. (2007) Hemostatic biomarkers in dogs with chronic congestive heart failure. Journal of Veterinary Internal Medicine, 21, 451-457.
24. Thim, L., Bjoern, S., Christensen, M., Nicolaisen, E.M., Lund-Hansen, T., Pedersen, A.H. & Hedner, U. (1988) Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry, 27, 7785-7793.
25. Tranholm, M., Kristensen, K., Kristensen, A.T., Pyke, C., Rojkjaer, R. & Persson, E. (2003) Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood, 102, 3615-3620.
26. Wells, M.J., Sheffield, W.P. & Blajchman, M.A. (1999) The clearance of thrombin-antithrombin and related serpin- enzyme complexes from the circulation: role of various hepatocyte receptors. Thrombosis and Haemostasis, 81, 325-337.
27. Wildgoose, P., Nemerson, Y., Hansen, L.L., Nielsen, F.E., Glazer, S. & Hedner, U. (1992) Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood, 80, 25-28.